Targeted Molecular Diagnostics has launched KRAS Mutation assay, a new clinical laboratory test, to identify colorectal cancer patients who may be resistant to EGFR targeted monoclonal antibody therapies.

Targeted Molecular Diagnostics has announced the availability of the PhosphoGuard kit for the preservation of phosphoproteins during tissue fixation and processing.